Journal: Journal of Neuroinflammation

Article Title: Bone marrow–derived emergency monopoiesis drives brain–lung axis injury after traumatic brain injury via IL-1

doi: 10.1186/s12974-025-03589-y

Figure Lengend Snippet: Global loss of Il11 alleviated emergency monopoiesis caused by TBI. A Schematic for experimental analysis of r Il1r1 +/+ and Il1r1 -knockout mice ( Il1r1 −/− ). B-C Metabolic activity of BM cell in skull, vertebra and femur were reduced in Il1r1 −/− mice (B, representative PET-CT images, C, quantitative analysis of PET-CT), as detected by 18 F-FDG uptake-based PET-CT (n = 6–12/group, one-way ANOVA). D Gating strategies for analyzing hematopoiesis including HSCs (Lineage − c-Kit + Sca-1 + CD48 − CD150 + ), CMPs (Lineage − c-Kit + Sca-1 − CD16/32 − CD34 + ), GMPs (Lineage − c-Kit + Sca-1 − CD16/32 + CD34 + ) and MDPs (Lineage − c-Kit + Sca-1 − CD16/32 − CD34 + CD115 + ) in the BM of mice. E-F Hematopoiesis analysis of LSK, HSC (E), CMPs, GMPs and MDPs (F) from skull BM of mice by flow cytometry 1 day post TBI (n = 6/group, one-way ANOVA). G-H Hematopoiesis analysis of LSK, HSCs (G), CMPs, GMPs and MDPs (H) from femur BM of mice by flow cytometry 1 day post TBI (n = 6/group, one-way ANOVA). I Gating strategies for analyzing monocytes (CD45 + CD11b + Ly6G − Ly6c +/− ). J Cell No. of monocytes (CD45 + CD11b + Ly6G − , left panel) and Ly6c + (right panel) monocytes in skull BM of mice measured by flow cytometry (n = 5–6/group, one-way ANOVA). K Cell No. of monocytes (CD45 + CD11b + Ly6G − , left panel) and Ly6c + (right panel) monocytes in femur BM of mice measured by flow cytometry (n = 5–6/group, one-way ANOVA). All data are expressed as means ± SEM

Article Snippet: Il1r1 −/− mouse were purchased from Cyagen (Suzhou, China).

Techniques: Knock-Out, Activity Assay, Positron Emission Tomography-Computed Tomography, Flow Cytometry

Journal: Journal of Neuroinflammation

Article Title: Bone marrow–derived emergency monopoiesis drives brain–lung axis injury after traumatic brain injury via IL-1

doi: 10.1186/s12974-025-03589-y

Figure Lengend Snippet: Inhibition of emergency monopoiesis through global loss of Il1r1 alleviated brain and lung injury caused by TBI. Representative images and quantification results of CD68 + CD86 + , or CD68 + CD206 + expression in brain (A) and lung (B) tissue of Il1r1 +/+ and Il1r1 −/− mice post TBI (bar = 20 μm, n = 6/group, one-way ANOVA). Quantification of neutrophils (C, left panel), overall macrophages (C, right panel), Ly6c + (D, left panel) and Ly6c − macrophages (D, right panel) in brain of mice detected by flow cytometry (n = 6/group, one-way ANOVA). E TBI and sham mice from Il1r1 +/+ and Il1r1 −/− group received MRI scans (Representative images of T2, CE-T1 and T2* map of 1 day post injury). FPI induced a large brain injury, which was significantly reduced in Il1r1 −/− mice (F, n = 3–5/group, two-way ANOVA). G mNSS tests, Rotarod tests and Coner test were conducted for evaluating the recovery of the Il1r1 +/+ and Il1r1 −/− mice challenged by sham or TBI (n = 5–8/group, one-way ANOVA). H 18 F-FDG uptake-based PET-CT imaging and quantification of the FDG uptake on the lung regions of Il1r1 +/+ and Il1r1 −/− mice 24 h post TBI (n = 5–7/group, one-way ANOVA). I-J ALI score (I) and H&E staining for lung tissues (J) of Il1r1 +/+ and Il1r1 −/− mice challenged by sham or TBI (n-6/group, bar = 50 μm, one-way ANOVA). K The ​pulmonary function (RL, RE, and Cdyn) of mice was measured at 3 days post-TBI of indicated group (n = 10/group, one-way ANOVA). All data are expressed as means ± SEM

Article Snippet: Il1r1 −/− mouse were purchased from Cyagen (Suzhou, China).

Techniques: Inhibition, Expressing, Flow Cytometry, Positron Emission Tomography-Computed Tomography, Imaging, Staining

Journal: Journal of Neuroinflammation

Article Title: Bone marrow–derived emergency monopoiesis drives brain–lung axis injury after traumatic brain injury via IL-1

doi: 10.1186/s12974-025-03589-y

Figure Lengend Snippet: Inhibition of emergency monopoiesis through hematopoiesis-specific loss of Il1r1 alleviated brain and lung injury caused by TBI. A Schematic for experimental analysis of chimeric mice. Quantification of neutrophils (B, left panel), overall macrophages (B, right panel), Ly6c + (C, left panel) and Ly6c − macrophages (C, right panel) in brain tissue by flow cytometry (n = 6/group, one-way ANOVA). D-E Representative images (left panel) and quantification results (right panel) of CD68 + CD86 + , or CD68 + CD206 + expression in brain (D) and lung (E) tissue of chimeric mice post TBI (bars = 20 μm, n = 6/group, one-way ANOVA). F Il1r1 +/+ : WT and Il1r1 −/− : WT BM-chimeric mice received MRI scans (Representative images of T2, CE-T1 and T2* map of day 1 post injury) and summary of multiple experiments (G, n = 3–5/group, two-way ANOVA). H mNSS test, Rotarod test and Corner test were conducted for evaluating the recovery of the Il1r1 +/+ : WT and Il1r1 −/− : WT BM-chimeric mice challenged by sham or TBI (n = 5–10/group, one-way ANOVA). I H&E staining of lung tissues and ALI score of Il1r1 +/+ : WT and Il1r1 −/− : WT BM-chimeric mice challenged by sham or TBI (n=6/group, bar = 50 μm, one-way ANOVA). All data are expressed as means ± SEM

Article Snippet: Il1r1 −/− mouse were purchased from Cyagen (Suzhou, China).

Techniques: Inhibition, Flow Cytometry, Expressing, Staining

Journal: NPJ breast cancer

Article Title: IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer.

doi: 10.1038/s41523-021-00305-w

Figure Lengend Snippet: Fig. 1 Depletion of IL-1B but not IL1R1 from the microenvironment promotes primary tumour growth. a Quantification (photons/sec (p/s)) of primary tumour growth in IL1R1fl/fl(n = 8 primary tumours from n = 4 mice) and IL1R1−/−(n = 8 primary tumours from n = 4 mice) mice up to 12 days of post-orthotopic injection of E0771-luc2-V5-GFP cells and b correspondent micrographs. c Quantification (p/s) of primary tumour growth in IL-1Bfl/fl(n = 7) and IL-1B−/−(n = 6) mice up to 26 days of post-orthotopic injection of E0771-luc2- GFP cells and d correspondent micrographs. IL-1Bfl/fl: n = 13 primary tumours from n = 7 mice (day 7 and 14); n = 12 primary tumours from n = 6 mice (day 20 and 26). IL-1B−/−: n = 12 primary tumours from n = 6 mice (day 7); n = 10 primary tumours from n = 6 mice (day 14, 20, and 26). 2.3-fold increase in primary tumour growth in IL-1B−/−mice (7.6 × 108 p/s) compared to IL-1Bfl/flmice (3.2 × 108 p/s) (P = 0.01). Data are mean +/−SEM, Two-way ANOVA with Sidak’s post-hoc test.

Article Snippet: The following plasmids were used for overexpression studies: IL-1B (MR226719L4, Origene), IL1R1 (MR227508L4, Origene), GFP (17448 pLenti CMV GFP Puro (658-5), Addgene), Luciferase (21474 pLenti CMV V5-LUC Blast (w567-1), Addgene).

Techniques: Injection

Journal: NPJ breast cancer

Article Title: IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer.

doi: 10.1038/s41523-021-00305-w

Figure Lengend Snippet: Fig. 3 Tumour-derived IL-1B restores the infiltration of innate immune cells that may display anti-tumour functions and inhibits primary tumour growth in an IL-1B deficient microenvironment. a, b Images and quantification of primary tumour development in IL-1Bfl/fl(n = 8 primary tumours from n = 4 mice) and IL-1B−/−(n = 10 primary tumours from n = 5 mice) mice after intra-ductal administration of E0771 Luc2 V5 IL-1B-GFP cells. Data are mean +/−SEM, Two-way ANOVA with Sidak’s post-hoc test. c, d Quantification of F4/80+ macrophages (c) and CD163+ macrophages (d) in tumour core and periphery in IL-1Bfl/fland IL-1B−/−mice. Data are mean ± SEM, Two-way ANOVA with Sidak’s post hoc test. e, f Quantification of CD34+ blood vessels and MPO+ neutrophils in IL-1Bfl/fland IL-1B−/−mice. Data are shown as mean +/−SEM, Two-tailed unpaired t-test. g, h Images and quantification of primary tumour development in IL1R1fl/fl(n = 18 primary tumours from n = 9 mice) and IL1R1−/−(n = 14 primary tumours from n = 7 mice) mice after intra-ductal administration of E0771 Luc2 V5 IL-1B-GFP. Normalised data are shown as mean +/−SEM, Two-tailed unpaired t-test.

Article Snippet: The following plasmids were used for overexpression studies: IL-1B (MR226719L4, Origene), IL1R1 (MR227508L4, Origene), GFP (17448 pLenti CMV GFP Puro (658-5), Addgene), Luciferase (21474 pLenti CMV V5-LUC Blast (w567-1), Addgene).

Techniques: Derivative Assay, Two Tailed Test

Journal: NPJ breast cancer

Article Title: IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer.

doi: 10.1038/s41523-021-00305-w

Figure Lengend Snippet: Fig. 4 IL-1B signalling enables breast cancer metastasis initiation. a, b Tumour proliferation after injection of E0771 luc2 V5 IL1R1-GFP cells in IL1R1fl/fl(n = 8 primary tumours from n = 4 mice) and IL1R1−/−(n = 6 primary tumours from n = 3 mice) mice. Data are mean +/−SEM, Two-way ANOVA with Sidak’s multiple comparisons test. c In vitro relative tumour growth of E0771 luc2 V5 GFP, IL-1B GFP or IL1R1 GFP cells upon stimulation with 40 pg/ml mouse recombinant IL-1B. Data are mean (+/−SEM), Two-way ANOVA with Sidak’s multiple comparison test (n = 6 technical repeats from two biological replicates). d Transwell cell migration of IL-1B overexpressing (P = 0.0009) and IL1R1 overexpressing (P < 0.0001) E0771 luc2 V5 cancer cells compared to control GFP-expressing cells (no treatment with exogenous IL-1B). Comparison of cell migration in vitro between E0771 luc2 V5 IL-1B GFP and IL1R1 GFP tumour cells (P = 0.0018). Data are mean (+/−SEM) cell number from 4 fields of view derived from three biological experiments (n = 12 technical repeats). Two-tailed unpaired t-test with Welch’s correction. e Representative images of haematoxylin-stained control, IL-1B and IL-1R1 overexpressing cells migrated through the membrane. Scale bar = 200 µm.

Article Snippet: The following plasmids were used for overexpression studies: IL-1B (MR226719L4, Origene), IL1R1 (MR227508L4, Origene), GFP (17448 pLenti CMV GFP Puro (658-5), Addgene), Luciferase (21474 pLenti CMV V5-LUC Blast (w567-1), Addgene).

Techniques: Injection, In Vitro, Recombinant, Comparison, Migration, Control, Expressing, Derivative Assay, Two Tailed Test, Staining, Membrane